Loading
Renal Cell Carcinoma Treatment · Journal article
Future Oncology · September 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase II feasibility study of response-based adaptive immunotherapy combining pembrolizumab-axitinib in advanced clear-cell RCC. The trial is designed to assess feasibility, safety, and preliminary efficacy signals of a novel treatment-scheduling approach, but is not powered to demonstrate clinical benefit and reports no efficacy data to date.
Phase II feasibility trial. Patients with metastatic or unresectable locally advanced clear-cell renal cell carcinoma. Intervention: Adaptive immunotherapy combination therapy with pembrolizumab-axitinib, with drug dosing modulated based on real-time tumor metrics.
Study aims to assess feasibility and clinical efficacy of adaptive immunotherapy combination with VEGFR-TKI in metastatic or unresectable locally advanced ccRCC Adaptive therapy approach modulates drug administration based on real-time tumor metrics to maintain sensitive cell populations and suppress resistant clones
No efficacy, safety, or feasibility data reported; this is a trial protocol or prospective registration only
This early-stage trial is exploratory and hypothesis-generating. Clinicians should not interpret this as evidence for a change in practice; results are pending and will need confirmation in a larger, comparative study before adoption.
Phase II feasibility and safety study of an adaptive immunotherapy-TKI combination in advanced RCC; early-stage design testing a novel treatment approach with surrogate endpoints rather than hard clinical outcomes.
As stated by the source record.
This early-stage trial is exploratory and hypothesis-generating. Clinicians should not interpret this as evidence for a change in practice; results are pending and will need confirmation in a larger, comparative study before adoption.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Kidney cancer is one of the 10 most common cancers affecting both men and women in the United States, accounting for 4% to 5% of all cancers. Most recent estimates have shown that about 81,610 new cases of kidney cancer will be diagnosed in 2024, with renal cell carcinoma (RCC). The treatment landscape of metastatic or unresectable locally advanced clear cell renal cell carcinoma (ccRCC) has changed over the past years with the approval of multiple combination regimens using immune checkpoint inhibitors (ICI) and vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI). However, this first‑line approach is associated with immense drug-related toxicity and financial burden. Recent research suggests that unlike traditional intermittent therapy, adaptive therapy modulates drug administration based on real-time tumor metrics to maintain a stable population of sensitive cells that suppress the growth of resistant clones. This phase II trial will assess the feasibility, patient acceptability, safety, and preliminary efficacy signals of a response-based multi-drug adaptive therapy approach with pembrolizumab-axitinib (pembro-axi) in patients with metastatic or unresectable locally advanced ccRCC.Clinical trial registration www.clinicaltrials.gov identifier is NCT06860386.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.